MSC Stock Overview

Underwriters Fully Exercise Option to Purchase Additional Shares HOUSTON , Feb. 4, 2025  /PRNewswire/ -- MSC Income Fund, Inc. (NYSE: MSIF) ("MSC Income" or the "Company"), an externally managed business development company, is pleased to announce that it closed the previously announced public offering of 5,500,000 shares of its common stock (the "Common Stock") at the public offering price of $15.53 per share. MSC Income's shares of Common Stock began trading on the New York Stock Exchange on January 29, 2025 under the ticker symbol "MSIF.

HOUSTON , Jan. 30, 2025 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street") is pleased to announce that MSC Income Fund, Inc. ("MSC Income"), an externally managed business development company ("BDC") for which Main Street's wholly owned registered investment adviser, MSC Adviser I, LLC ("MSC Adviser"), serves as the investment adviser and administrator, recently closed a follow-on public offering of 5,500,000 shares of its common stock at $15.53 per share and, in connection with the offering, MSC Income's shares of common stock began trading on the New York Stock Exchange on January 29, 2025 under the ticker symbol "MSIF."  MSC Income received gross proceeds from the offering of approximately $85.4 million, which it intends to use, after the fees and expenses associated with the offering, to repay outstanding debt borrowed under its credit facilities, and then through re-borrowing under the credit facilities, to make investments in accordance with its investment objective and strategies, pay operating expenses and other cash obligations, and for general corporate purposes.

HOUSTON , Jan. 28, 2025 /PRNewswire/ -- MSC Income Fund, Inc. ("MSC Income" or the "Company"), an externally managed business development company, today announced that it priced its public offering of 5,500,000 shares of its common stock (the "Common Stock") at $15.53 per share. MSC Income's shares of Common Stock are expected to begin trading on the New York Stock Exchange on January 29, 2025 under the symbol "MSIF.

MELVILLE, N.Y. and DAVIDSON, N.C.

MSC Industrial Direct Co., Inc. MSM will release its first-quarter financial results, before the opening bell, on Wednesday, Jan. 8, 2025.

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil® (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States. RYONCIL is the only MSC therapy approved in the U.S. for any indication, and the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents and teenagers.

MELVILLE, N.Y. and DAVIDSON, N.C.

MELVILLE, N.Y. and DAVIDSON, N.C.

MELVILLE, N.Y. and DAVIDSON, N.C.